Publications
Selected Publications
Li J, Mestre TA, Mollenhauer B, Frasier M, Tomlinson JJ, Trenkwalder C, Ramsay T, Manuel D, Schlossmacher MG. Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination. NPJ Parkinsons Dis. 2022 Jul 29;8(1):94. doi: 10.1038/s41531-022-00360-5. PMID: 35906250; PMCID: PMC9338052.
Schlossmacher MG, Graybiel A. Conversations with Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson’s: How Do You Wish to be Remembered? Mov Disord. 2020 Nov;35(11):1922-1932. doi: 10.1002/mds.28316. Epub 2020 Oct 14. PMID: 33053225; PMCID: PMC7756664.
Tokarew, Jacqueline M., et al. "Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites." Acta neuropathologica 141.5. 2021; 725-754.
Oliveira, Luis, et al. "Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease." npj Parkinson's Disease 7.1. 2021; 1-23.
Sircar, Esha, et al. "Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on the pathogenesis of Parkinson's disease." Archives of Biochemistry and Biophysics 704. 2021; 108869.
Sanyal, Anwesha, et al. "Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition." Movement Disorders 35.5 2020; 760-773.
Shutinoski B, et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med. 2019 Sep 25;11(511). pii: eaas9292. doi: 10.1126/scitranslmed.aas9292.
Tomlinson JJ et al. Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. J Neural Transm 2017; 124(6): 721-738
Schlossmacher MG et al. Modelling idiopathic Parkinson disease as a
complex illness can inform incidence rate in healthy adults : the PREDIGT
score. Eur J Neuroci. 2017;
45(1) :175-191
Cullen V* et al. Acid beta-glucosidase mutations linked to Gaucher disease, Parkinson's and Lewy body dementia dysregulate alpha-synuclein in vivo. Ann Neurol 2011;69:940-53
*This paper was awarded the editor's ‘Annals of Neurology Prize' in 2012
Hakimi M et al. Parkinson's-linked
LRRK2 is expressed in immune cells and upregulated after the recognition of
microbial structures. J Neural
Transm 2011;118:795-808
Mollenhauer B* et al. Cerebrospinal fluid values of alpha-synuclein and tau in patients
presenting with parkinsonism. Lancet Neurol
2011;10:230-40 and Lancet Neurol 2011;10:681-3;
*See also the opinion piece published
in: Lancet Neurol 2011;10(3):203-5
All Other Publications
Shutinoski B, Patel R, Tomlinson JJ, Schlossmacher MG, Sad S. Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome. Microbes Infect. 2019 Aug 17. pii: S1286-4579(19)30085-1. doi: 10.1016/j.micinf.2019.08.002.
Xu H, Boucher FR, Nguyen TT, Taylor GP, Tomlinson JJ, Ortega RA, Simons B, Schlossmacher MG, Saunders-Pullman R, Shaw W, Bennett SAL. DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid. J Lipid Res. 2019 Jan;60(1):200-211. doi: 10.1194/jlr.D089797. Epub 2018 Nov 9.
Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S. K45A mutation of RIPK1 results in poor
necroptosis and cytokine signaling in macrophages, which impacts inflammatory
responses in vivo. Cell Death Differ.
2016 23(1) :1628-1637
Mollenhauer B et al. Biological confounders for the values of
cerebrospinal fluid protein in Parkinson’s disease and related disorders. J Neurochem. 2016; 139 Suppl
1 :290-317
Fava VM et al. A Missense LRRK2 Variant Is a Risk Factor for Excessive
Inflammatory Responses in Leprosy. PLoS Negl Trop Dis. 2016;
10(2) :e0004412.
* This paper is from
Dr. Erwin Schurr’s team as part of the CLINT Consortium
Rocha JD et al. LRRK2 and Nod2 promote lysozyme sorting in Paneth
cells. Nat Immunol. 2015;
16(9):898-900.
Gray MT et al. Alpha-synuclein in the appendiceal mucosa of
neurologically intact subjects. Mov
Disord. 2014; 29(8) :991-998
Sardi SP et al. Mutant GBA1 expression
and synucleinopathy risk: First insights from cellular and mouse models. Neurodeg Dis 2012 ;10(1-4):195-202
Kitada T*, Tomlinson
JJ* et al. Considerations regarding the etiology and treatment of recessive versus
idiopathic Parkinson disease. Curr Treat Opt
Neurol 2012;14:230-40
Cullen
V*, Lindfors M* et al. Cathepsin D expression affects the processing, aggregation
and toxicity of a-synuclein
in vivo. Mol
Brain 2009;2:5(1-17)
* This paper was awarded the editor’s ‘Molecular Brain Award’ in
2012
Tomlinson
JJ* et al. Identifying targets in a-synuclein
metabolism to treat Parkinson’s and related disorders. Protein Misfolding
Diseases. Editors: M. Ramirez- Alvarado, J. Kelly and C. Dobson. Wiley & Son Inc. 2010;37:817-42
Klein C et al. Translational Research in Neurology
and Neuroscience 2011: Movement Disorders. Arch Neurol 2011;68:709-16
Mollenhauer
B et al. Total CSF a-synuclein is lower in de novo Parkinson’s disease patients
than in healthy controls. Neurosci Lett 2013; 532:44-8
PubMed Listings
